Dendreon to Present at Scientific and Financial Conferences Next Week
May 19 2005 - 9:01AM
PR Newswire (US)
Dendreon to Present at Scientific and Financial Conferences Next
Week - Poster Presentation at American Urological Association
Annual Meeting SEATTLE, May 19 /PRNewswire-FirstCall/ -- Dendreon
Corporation (NASDAQ: DNDN) today announced that the D9905 Phase 2
clinical trial results of Provenge(R) (APC8015), the Company's
investigational immunotherapy for the treatment of prostate cancer,
will be presented at the 2005 American Urological Association (AUA)
Annual Meeting, taking place in San Antonio, TX, May 21-26. In
addition, management will present at the Needham Biotechnology
Conference next week. Details are as follows: Immunotherapy
(APC8015) for Androgen Dependent, Biochemically-Relapsed Prostate
Cancer. Poster presentation on Tuesday, May 24, 8:00 a.m. - 12:00
p.m. Central Time, Ballroom A, Presenter: Robert M. Hershberg, M.D.
Dendreon Corporation. Fourth Annual Needham Biotechnology
Conference Management will present at Needham's Fourth Annual
Biotechnology Conference on Thursday, May 26 at 8:30 a.m. Eastern
Time at the New York Palace Hotel. The presentation will be webcast
live and available for replay from the "Investors/Webcasts &
Presentations" section of Dendreon's website,
http://www.dendreon.com/ and will be available for replay for 90
days. Dendreon Corporation is a biotechnology company whose mission
is to target cancer and transform lives through the development of
innovative cancer treatments. In addition to its immunotherapies in
clinical and preclinical development for a variety of cancers,
Dendreon's product pipeline also includes monoclonal antibody and
small molecule product candidates. Dendreon has research and
development alliances with Genentech, Inc., Abgenix, Inc. and Dyax
Corp. For more information about the company and its programs,
visit http://www.dendreon.com/. NOTE: Except for historical
information contained herein, this news release contains
forward-looking statements that are subject to risks and
uncertainties that may cause actual results to differ materially
from the results discussed in the forward-looking statements,
particularly those risks and uncertainties inherent in the process
of discovering, developing and commercializing drugs that are safe
and effective for use as human therapeutics. Further information on
the factors and risks that could affect Dendreon's business,
financial condition and results of operations are contained in
Dendreon's filings with the U.S. Securities and Exchange
Commission, which are available at http://www.sec.gov/. DATASOURCE:
Dendreon Corporation CONTACT: Monique M. Greer, Sr. Director,
Corporate Communications of Dendreon Corporation, +1-206-829-1500
Web site: http://www.dendreon.com/
Copyright